Genome Engineering with TALE and CRISPR Systems in Neuroscience.
Recent advancement in genome engineering technology is changing the landscape of biological research and providing neuroscientists with an opportunity to develop new methodologies to ask critical research questions. This advancement is highlighted by the increased use of programmable DNA-binding agents (PDBAs) such as transcription activator-like effector (TALE) and RNA-guided clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated (Cas) systems. These PDBAs fused or co-expressed with various effector domains allow precise modification of genomic sequences and gene expression levels. These technologies mirror and extend beyond classic gene targeting methods contributing to the development of novel tools for basic and clinical neuroscience. In this Review, we discuss the recent development in genome engineering and potential applications of this technology in the field of neuroscience.
Neurobiology of Disease Graduate Program, Mayo Graduate School Rochester, MN, USA.
Han B
HB
Lee
Department of Biochemistry and Molecular Biology, Mayo Clinic Rochester, MN, USA.
Brynn N
BN
Sundberg
Department of Biochemistry and Molecular Biology, Mayo Clinic Rochester, MN, USA.
Ashley N
AN
Sigafoos
Neurobiology of Disease Graduate Program, Mayo Graduate SchoolRochester, MN, USA; Department of Biochemistry and Molecular Biology, Mayo ClinicRochester, MN, USA.
Karl J
KJ
Clark
CRISPR; Cas9; TALE; TALEN; ZFN; genome engineering; neuroscience